First presentation of preclinical data for
ESSA's androgen receptor (AR) N-terminal domain degraders
ANITen bAsed Chimera (ANITAC™)
degraders degrade full length, mutant and splice variant forms of
AR that are expressed in CRPC patients
Orally bioavailable ANITAC degraders show
robust functional activity in cellular models including inhibition
of AR transcriptional activity and cell viability
SOUTH SAN FRANCISCO,
California and VANCOUVER,
Canada, March 8,
2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or
the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical
company focused on developing novel therapies for the treatment of
prostate cancer, today announced that it will present preclinical
data for its first generation of androgen receptor (AR) N-terminal
domain degraders at the 2022 American Association for Cancer
Research (AACR) Annual Meeting. The ANITen bAsed Chimera (ANITAC™)
degraders suppressed AR transcriptional activity and decreased the
viability of prostate cancer cells in castration-resistant prostate
cancer (CRPC) preclinical models. ANITAC degraders degraded
full length, mutant and splice variant forms of AR that are
expressed in CRPC patients.
Poster presentation details are as follows:
Title: Androgen receptor (AR) N-Terminal Domain
degraders can degrade AR full length and AR splice variants in CRPC
Authors: Nan Hyung Hong, et al.
Session Title: Protein Degraders and Proteasome
Session Date and Time: Sunday, April
10, 2022 | 1:30 p.m. - 5:00 p.m.
Location: New Orleans Convention Center, Exhibit Halls
D-H, Poster Section 26
The e-poster will be available to 2022 AACR Annual Meeting
attendees and on the Company's website at www.essapharma.com on
April 8, 2022, at 1:00 p.m. ET.
About ESSA Pharma Inc.
ESSA is a clinical-stage
pharmaceutical company focused on developing novel and proprietary
therapies for the treatment of patients with prostate cancer. For
more information, please visit www.essapharma.com and follow us on
Twitter under @ESSAPharma.
About Prostate Cancer
Prostate cancer is the
second-most commonly diagnosed cancer among men and the fifth most
common cause of male cancer death worldwide (Globocan, 2018).
Adenocarcinoma of the prostate is dependent on androgen for tumor
progression and depleting or blocking androgen action has been a
mainstay of hormonal treatment for over six decades. Although
tumors are often initially sensitive to medical or surgical
therapies that decrease levels of testosterone, disease progression
despite castrate levels of testosterone can lead to mCRPC. The
treatment of mCRPC patients has evolved rapidly over the past ten
years. Despite these advances, many patients with mCRPC fail or
develop resistance to existing treatments, leading to continued
disease progression and limited survival rates.
SOURCE ESSA Pharma Inc